Drug Transporters: Their Role and Importance in the Selection and Development of New Drugs

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 2, 2002, Pages 93-108

  Mizuno, Naomi ^a   Sugiyama, Yuichi ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

drug development; drug discovery; Transporter

Indexed keywords

EID: 0002674396     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.93     Document Type: Review

References (148)

1. Kusuhara, H. and Sugiyama, Y.: Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control Release, 78: 43-54 (2002).
2. Kim, R. B.: Transporters in drug disposition. Curr. Opin. Drug Discov. Develop., 3: 94-101 (2000).
3. Zhang, L., Brett, C. M. and Giacomini, K. M.: Role of organic cation transporters in drug absorption and elimination. Ann. Rev. Pharmacol. Toxicol., 38: 431-460 (1998).
4. Koepsell, H.: Organic cation transporters in intestine, kidney, liver, and brain. Ann. Rev. Physiol., 60: 243-266 (1998).
5. Meijer, D. K., Hooiveld, G. J., Schinkel, A. H., van Montfoort, J. E., Haas, M., de Zeeuw, D., Moolenaar, F., Smit, J. W. and Meier, P. J.: Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery. Nephrol. Dial. Transplant., 14: 1-3 (1999).
6. Hirohashi, T., Suzuki, H., Takikawa, H. and Sugiyama, Y.: ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (mrp3). J. Biol. Chem., 275: 2905-2910 (2000).
7. Hirohashi, T., Suzuki, H. and Sugiyama, Y.: Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem., 274: 15181-15185 (1999).
8. Gao, B. and Meier, P. J.: Organic anion transport across the chroid plexus. Microsc. Res. Tech., 52: 60-64 (2001).
9. Suzuki, H. and Sugiyama, Y.: Transporters for bile acids and organic anions. In Sadee, W. and Amidon, G. (ed.): Membrane transporters as drug targets, New York, Kluwer Academic/Plenum Publishing Co., 1999, pp. 387-439.
10. White, R. E.: High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu. Rev. Pharmacol. Toxicol., 40: 133-57 (2000).
11. Roberts, S. A.: High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica, 31: 557-589 (2001).
12. Kusuhara, H. and Sugiyama, Y.: Drug-drug interactions involving the membrane transport process. In Rodrigues, A. D. (ed.): Drug-drug interactions, New York, Marcell Dekker, Inc., 2001, pp. 123-188.
13. Ayrton, A. and Morgan, P.: Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 31: 469-497 (2001).
14. Dresser, M. J., Leabman, M. K. and Giacomini, K. M.: Transporters involved in the elimination of drugs in the kidney: oraganic anion transporters and organic cation transporters. J. Pharm. Sci., 90: 397-421 (2001).
15. Meier, P. J., Eckhardt, U., Schroeder, A., Hagenbuch, B. and Stieger, B.: Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology, 26: 1667-77 (1997).
16. Hooiveld, G. J., van Montfoort, J. E., Meijer, D. K., Muller, M.: Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur. J. Pharm. Sci., 12: 525-43 (2001).
17. Lee, V. H., Sporty, J. L. and Fandy, T. E.: Pharmacogenomics of drug transporters: the next drug delivery challenge. Adv. Drug Deliv. Rev., 50: S33-S40 (2001).
18. Kullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J. and Hagenbuch, B.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 120: 525-533 (2001).
19. Inui, K., Terada, T., Masuda, S. and Saito, H.: Physiological and pharmacological implications of peptide transporters, PEPT1 and PEPT2. Nephrol. Dial. Transplant., 15: 11-13 (2000).
20. Konig, J., Cui, Y., Nies, A. T. and Keppler, D.: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem., 275: 23161-8 (2000).
21. Tamai, I., Nezu, J., Uchino, H., Sai, Y., Oku, A., Shimane, M. and Tsuji, A.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun., 273: 251-60 (2000).
22. Kusuhara, H., Suzuki, H. and Sugiyama, Y.: The role of P-glycoprotein and canalicular multispecific organic anion transporter (CMOAT) in the hepatobiliary excretion of drugs. J. Pharm. Sci., 87: 1025-1040 (1998).
23. Borst, P., Evers, R., Kool, M. and Wijnholds, J.: The multidrug resistance protein family. Biochim. Biophys. Acta., 1461: 347-357 (1999).
24. Greiner, B., Eichelbaum, M., Fritz, P., Kreichigauer, H. P., von Richter, O., zundler, J. and Kroemer, H. K.: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest., 104: 147-153 (1999).
25. Masuda, S., Uemoto, S., Hashida, T., Inomata, Y., Tanaka, K. and Inui, K.: Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin. Pharmacol. Ther., 68: 93-103 (2000).
26. Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T. and Sugiyama, Y.: Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver. J. Biol. Chem., 273: 1684-1688 (1998).
27. Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T. and Sugiyama, Y.: Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am. J. Physiol., 272: G16-G22 (1997).
28. Hirohashi, T., Suzuki, H., Chu, X. Y., Tamai, I., Tsuji, A. and Sugiyama, Y.: Functional and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J. Pharmacol. Exp. Ther., 292: 265-270 (2000).
29. Gotoh, Y., Suzuki, H., Kinoshita, S., Hirohashi, T., Kato, Y. and Sugiyama, Y.: Involvement of an organic anion transporter (canalicular multispecific organic anion transporter multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J. Pharmacol. Exp. Ther., 292: 433-439 (2000).
30. Okudaira, N., Tatebayashi, T., Speirs, G. C., Komiya, I. and Sugiyama, Y.: A study of the intestinal absorption of and ester type prodrug, ME3229 in rats: active efflux transport as a cause of poor bioavailability of the active drug. J. Pharmacol. Exp. Ther., 294: 580-587 (2000).
31. Okudaira, N., Komiya, I. and Sugiyama, Y.: Polarized efflux of mono-and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIbWIIIa receptor antagonist, in rat small intestine. J. Pharmacol. Exp. Ther., 295: 717-723 (2000).
32. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J. and Schellens, J. H. M.: Subcellular localization and distribution of the breast cancer resistance protein transporter in nomal human tissues. Cancer Res., 61: 3458-3464 (2001).
33. Jonker, J.W., Smit, J. W., Brinkhuis, R. F., Maliepaaed, M., Beijnen, J. H., Schellens, J. H. M. and Schinkel, A. H.: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer. Inst., 92: 1651-1656 (2000).
34. Sikic, B. I., Advani, R., Fisher, G. A., Halsey, J., Cohen, P. and Lum, B. L.: Enhanced bioavailability of oral paclitaxel by valspodar (PSC833), an inhibitor of small bowel P-glycoprotein and cytochrome P450. Clin. Cancer Res., 6: 4580S (2000).
35. Yamazaki, M., Suzuki, H. and Sugiyama, Y.: Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res., 13: 497-513 (1996).
36. Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W. P. and Kirchgessner, T. G.: A novel human hepatic organic anion transporting polypeptide (OATP2). J. Biol. Chem., 274: 37161-8 (1999).
37. Nakanishi, T., Tamai, I., Sai, Y., Sasaki, T. and Tsuji, A.: Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer. Res., 58: 4118-22 (1997).
38. Nakanishi, T., Tamai, I., Takagi, A. and Tsuji, A.: Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer, 88: 274-80 (2000).
39. Suzuki, H., Terasaki, T. and Sugiyama, Y.: Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv. Drug. Deliv. Rev., 25: 257-85 (1997).
40. Kusuhara, H. and Sugiyama, Y.: Efflux transport system for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1, 2). Drug. Discov. Today, 6: 150-156(1), 206-212(2) (2001).
41. Tamai, I. and Tsuji, A.: Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci., 89: 1371-1388 (2000).
42. Sadeque, A. J. M., Wandel, C., He, H., Shah, S. and Wood, A. J. J.: Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther., 68: 231-237 (2000).
43. Ishikawa, T., Bao, J. J., Yamane, Y., Akimaru, K., Frindrich, K., Wright, C. D. and Kuo, M. T.: Coordinate induction of MRP GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J. Biol. Chem., 271: 14981-8 (1996).
44. Kuo, M. T., Bao, J., Furuichi, M., Yamane, Y., Gomi, A., Savaraj, N., Masuzawa, T. and Ishikawa, T.: Frequent coexpression of MRP GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem. Pharmacol., 55: 605-15 (1998).
45. Kool, M., van der Linden, M., de Haas, M., Scheer, G. L., de Vree, J. M. L., Smith, A. J., Jansen, G., Peters, G.J., Ponne, N., Scheper, R. J., Oude-Elferink, R. P. J. Baas, F. and Borst, P.: MRP3 and organic anion transporter able to transport anticancer drugs. Proc. Natl. Acad. Sci. USA, 96: 6914-19 (1999).
46. Konig, J., Nies, A. T., Cui, Y., Leier, I. and Keppler, D.: Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta., 1461: 377-94 (1999).
47. Kuwano, M., Toh, S., Uchiumi, T., Takano, H., Kohno, K. and Wada, M.: Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug. Des., 14: 123-31 (1999).
48. Cole, S. P. and Deeley, R. G.: Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays, 20: 931-40 (1998).
49. Dantzig, A. H., Law, K. L., Cao, J. and Starling, I. J.: Reversal of multidrug resistance by the P-glycoprotein modulator, LY335989, from the bench to the clinic. Curr. Med. Chem., 8: 39-50 (2001).
50. Malingre, M. M., Beijnen, J. H., Rosing, H., Koopman, F. J., Jewell, R. C., Paul, E. M., Ten, Bokkel, Huinink, W.W. and Schellens, J. H.: Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer, 84: 42-47 (2001).
51. Mistry, P., Stewart, A. J., Dangerfield, W., Okiji, S., Liddle, C., Bootle, D., Plumb, J. A., Templeton, D. and Charlton, P.: In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res., 61: 749-58 (2001).
52. Ishikawa, T., Kuo, M. T., Furuta, K. and Suzuki, M.: The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design. Clin. Chem. Lab. Med., 38: 893-7 (2000).
53. Huisman, M. T., Smit, J. W. and Schinkel, A. H. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS, 14: 237-242 (2000).
54. Lee, C. G., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I. and Dey, S.: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry, 37: 3594-3601 (1998).
55. Hoetelmans, R. M. W.: Sanctuary site in HIV-1 infection. Antivir. Ther., 3 (Suppl 4): 13-17 (1998).
56. Turriziani, O., Marco, P. D. and Antonelli, G.: May the drug transporter P-glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors? Antimicrob. Agents Chemother., 44: 473-474 (2000).
57. Smit, J. W., Huisman, M. T., van Tellingen, O., Wiltshire, H. R. and Schinkel, A. H.: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest., 104: 1441-1447 (1999).
58. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J. J., Roden, D. M. and Wilkinson, G. R.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 101: 289-294 (1998).
59. Choo, E. F., Leake, B., Wandel, C., Imamura, H., Wood, A. J., Wilkinson, G. R. and Kim, R. B.: Pharmacological inhibition of p-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos., 28: 655-660 (2000).
60. Merry, C., Barry, M. G., Mulcahy, F., Ryan, M., Heavey, J., Tjia, J. F., Gibbons, S. E., Breckenridge, A. M., and Back, D. J.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infect-ed patients. AIDS, 11: F29-F33 (1997).
61. Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Te Riele, H. P. J., Berns, A. J. M. and Borst P.: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77: 491-502 (1994).
62. Jonker, J. W., Wagenaar, E., Mol, C. A. A. M., Buitelaar, M., Koepsell, H., Smit, J. W., Schinkel, A. H.: Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol. Cell. Biol., 21: 5471-7 (2001).
63. Wijnholds, J., Evers, R., van Leusden, M. R., Mol, C. A., Zaman, G. J., Mayer, U., Beijnen, J. H., van der Valk, M., Krimpenfort, P., Borst, P.: Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med., 3: 1275-9 (1997).
64. Wijnholds, J., de Lange, E. C. M., Scheffer, G. L., van den Berg, D.-J., Mol, C. A. A. M., van der Valk, M., Schinkel, A. H., Scheper, R. J., Breimer, D. D. and Borst, P.: Multidrug resistance protein 1 protects the chroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest., 105: 279-85 (2000).
65. Sekine, T., Cha, S. H. and Endou, H.: The multispecific organic anion transporter (OAT) family. Pflugers Arch., 440: 337-50 (2000).
66. Hosoyamada, M., Sekine, T., Kanai, Y. and Endou, H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol., 276: F122-F128 (1999).
67. Cihlar, T., Lin, D. C., Pritchard, J. B., Fuller, M. D., Mendel, D. B. and Sweet, D. H.: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol., 56: 570-80 (1999).
68. Jung, K. Y., Takeda, M., Kim, D. K., Tojo, A., Narikawa, S., Yoo, B. S., Hosoyamada, M., Cha, S. H., Sekine, T. and Endou, H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci., 69: 2123-35 (2001).
69. Wada, S., Tsuda, M., Sekine, T., Cha, S. H., Kimura, M., Kanai, Y. and Endou, H: Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J. Pharmacol. Exp. Ther., 294: 844-9 (2000).
70. Jariyawat, S., Sekine, T., Takeda, M., Apiwattanakul, N., Kanai, Y., Sophasan, S. and Endou, H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J. Pharmacol. Exp. Ther., 290: 672-7 (1999).
71. Cihlar, T., Ho, E. S., Lin, D. C. and Mulato, A. S.: Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids, 20: 641-8 (2001).
72. Cihlar, T. and Ho, E. S.: Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal. Biochem., 283: 49-55 (2000).
73. Mulato, A. S., Ho, E. S. and Cihlar, T.: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J. Pharmacol. Exp. Ther., 295: 10-15 (2000).
74. Apiwattanakul, N., Sekine, T., Chairoungdua, A., Kanai, Y., Nakajima, N., Sophasan, S. and Endou, H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol. Pharmacol., 55: 847-54 (1999).
75. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T.-L., Hendricks, C., Rock, M. K. and Donehower, R. C.: Phase I and Pharmacological study of novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res., 54: 427-436 (1994).
76. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M. and Hoshi, A.: Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res., 84: 697-702 (1993).
77. Kanedam N. and Yokokura, T.: Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res., 50: 1721-1725 (1990).
78. Chu, X. Y., Kato, Y., Niinuma, K., Sudo, K. I., Hakusui, H. and Sugiyama, Y.: Multispecific organic anion transporter (CMOAT) is responsible for the bilialy excretion of the camptothecin derivative irinotecan, CPT-11, and its metabolites in rats. J. Pharmacol. Exp. Ther., 281: 304-314 (1997).
79. Chu, X. Y., Kato, Y. and Sugiyama, Y.: Multiplicity of biliary excretion mechanisms for the camptothecin dericative irinotecan, CPT-11, and its metabolites in rats. Cancer Res., 57: 1934-1938 (1997).
80. Chu, X., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E. and Sugiyama, Y.: Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters. Cancer Res., 58: 5137-5143 (1998).
81. Keppler, D. and Konig, J.: Hepatic secretion of conjugated drugs and endogenous substance. Semin. Liver Dis., 20: 265-272 (2000).
82. Kullak-Ublick, G. A., Stieger, B., Hagenbuch, B. and Meier, P. J.: Hepatic transport of bile salts. Semin. Liver Dis., 20: 273-92 (2000).
83. Inui, K., Masuda, S. and Saito, H.: Cellular and molecular aspects of drug transport in the kidney. Kidney Int., 58: 944-958 (2000).
84. Oguchi H., Miyasaka, M., Koiwai, T., Tokunaga, S., Hara, K., Sato, K., Yoshie, T., Shioya, H. and Furuta, S.: Pharmacokinetics of temocapril and enalapril in patients with various degree of renal insufficiency. Clin. Pharmacokinet., 24: 421-427 (1993).
85. Ishizuka, H., Konno, K., Naganuma, H., Sasahara, K., Kawahara, Y., Niinuma, K., Suzuki, H. and Sugiyama, Y.: Temocaprilat, a novel angiotensin converting enzyme inhibitor, is excreted into bile via an ATP-dependent active transporter (CMOAT) that is deficient in Eisai hyper-biliruminemic mutant rats (EHBR). J. Pharmacol. Exp. Ther., 280: 1304-1311 (1997).
86. Ishizuka, H., Konno, K., Shiina, T., Naganuma, H., Nishimura, K., Ito, K., Suzuki, H. and Sugiyama, Y.: Species differences in the transport activity for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther., 290: 1324-30 (1999).
87. Konig, J., Cui, Y., Nies, N. T. and Keppler, D.: A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol., 278: G156-G164 (2000).
88. Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., Matsuno, S. and Yawo, H.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem., 274: 17159-63 (1999).
89. Kakyo, M., Unno, M., Tokui, T., Nakagomi, R., Nishio, T., Iwasashi, H., Nakai, D., Seki, M., Suzuki, M., Naitoh, T., Matsuno, S., Yawo, H. and Abe, T.: Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1. Gastroenterology, 117: 770-5 (1999).
90. Zhang, L., Dresser, M. J., Gray, A. T., Yost, S. C., Terashita, S. and Giacomini, K. M.: Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol., 51: 913-21 (1997).
91. Kovaril, J. M., Rigaudy, L., Guerret, M., Gerbeau, C. and Rost, K. L.: Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin. Pahrmacol. Ther., 66: 391-400 (1999).
92. Hedman, A., Angelin, B., Arvidsson, A., Beck, O., Dahlqvist, R., Nilsson, B., Olsson, M. and Schenck-Gustafsson, K.: Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin. Pharmacol. Ther., 49: 256-62 (1991).
93. Hedman, A., Angelin, B., Arcidsson, A., Dahlqvist, R. and Nilsson, B.: Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin. Pharmacol. Ther., 47: 20-26 (1990).
94. Muck, W., Mai, I., Fritsche, L., Ochmann, K., Rohde, G., Unger, S., Johne, A., Bauer, S., Budde, K., Roots, I., Neumayer, H. and Kuhlmann, J.: Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther., 65: 251-61 (1999).
95. Sasaki, M., Suzuki, H., Ito, K., Abe, T. and Sugiyama, Y.: Transcellular transport of organic anions across double-transfected MDCK II cell monolayer expressing both human organic anion transporting polypeptide (OATP2/SLC21A6) and multidrug resistance associated protein 2 (MRP2/ABCC2). J. Biol. Chem., in press.
96. Alexandridis, G., Pappas, G. A. and Elisaf, M. S.: Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am. J. Med., 109: 261-262 (2000).
97. SoRelle, R.: Baycol withdrawn from market. Circulation, 104: E9015-E9016 (2001).
98. Schwarz, U. I., Gramatte, T., Krappweis, J., Oertel, R. and Kirch, W.: P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int. J. Clin. Pharmacol. Ther., 38: 161-167 (2000).
99. Suzuki, H. and Sugiyama, Y.: Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci., 12: 3-12 (2000).
100. Wacher, V. J., Salphati, L. and Benet, L. Z.: Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev., 46: 89-102 (2001).
101. Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R. and Kim, R. B.: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos., 27: 866-871 (1999).
102. Bailey, D. G., Dresser, G. K., Munoz, C. Freeman, D. J. and Kim, R. B.: Reduction of fexofenadine bioavailability by fruit juices [abstract]. Clin. Pharmacol. Ther., 69: 21 (2001).
103. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I.: Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort. Clin. Pharmacol. Ther., 66: 338-345 (1999).
104. Durr, D., Stieger, B., Kullak-Ublick, G. A., Rentsch, K. M., Steinert, H. C., Meier, P. J. and Fattinger, K.: St John's wort induces intestinal P-glycoprotein MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther., 68: 598-604 (2000).
105. Fromm, M. F., Kauffmann, H. M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W. and Schrenk, D.: The effect of rifampin treatment on intestinal expression of human MRP transporters. Am. J. Pathol., 157: 1575-1580 (2000).
106. Synold, T. W., Dussault, I. and Forman, B. M.: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med., 7: 584-590 (2001).
107. Geick, A., Eichelbaum, M. and Burk, O.: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem., 276: 14581-14587 (2001).
108. Masuyama, H., Hiramatsu, Y., Mizutani, Y., Inoshita, H. and Kudo, T.: The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol. Cell Endocrinol., 172: 47-56 (2001).
109. Ueda, K., Kato, Y., Komatsu, K. and Sugiyama, Y.: Inhibition of the bilialy excretion of methotrexate by probenecid in rats: Quantitative prediction of the interaction from in vitro data. J. Pharmacol. Exp. Ther., 297: 1036-1043 (2001).
110. Mayatepek, E., Nezu, J., Tamai, I., Oku, A., Katsura, M., Shimane, M. and Tsuji, A.: Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency. Hum. Mutat., 15: 118 (2000).
111. Ito, S., Ieiri, I., Tanabe, M., Suzuki, A., Higuchi, S. and Otsubo, K.: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics, 11: 175-184 (2001).
112. Kerb, R., Hoffmeyer, S. and Brinkmann, U.: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenetics, 2: 51-64 (2001).
113. Nezu, J., Tamai, I., Oku, A., Ohashi, R., Yabuuchi, H., Hashimoto, N., Nikaido, H., Sai, Y., Koizumi, A., Shoji, Y., Takeda, G., Matsuishi, T., Yoshino, M., Kato, H., Ohura, T., Tsujimoto, G., Hayakawa, J., Shimane, M. and Tsuji, G.: Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat. Genet., 21: 91-94 (1999).
114. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. and Brinkmann, U.: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 97: 3473-8 (2000).
115. Cascorbi, I., Gerlogg, T., Johne, A., Meisel, C., Hoffmeyer, S., Schwab, M., Schaeffeler, E., Eichelbaum, M., Brinkmann, U. and Roots, I.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transpsorter MDR1 gene in white subjects. Clin. Pharmacol. Ther., 69: 169-174 (2001).
116. Ameyaw, M. M., Regateiro, F., Li, T., Liu, X., Tariq, M., Mobarek, A., Thornton, N., Folayan, G. O., Githang's, J., Indalo, A., Ofori-Adjei, D., Price-Evans, D. A. and McLeod, H. L.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics, 11: 217-221 (2001).
117. Kim, R. D., Leake, B. F., Choo, E. F., Dresser, G. K., Kubba, S. V., Schwarz, U. I., Taylor, A., Xie, H. G., McKinsey, J., Zhou, S., Lan, L. B., Schuetz, J. D., Schuetz, E. G. and Wilkinson, G. R.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther., 70: 189-99 (2001).
118. Tirona, R. G., Leake, B. F., Merino, G. and Kim, R. B.: Polymorphisms in oatp-c. Identification of multiple allelic variants associated with altered transport activity among European-and African-americans. J. Biol. Chem., 276: 35669-35675 (2001).
119. Adachi, Y., Suzuki, H. and Sugiyama, Y.: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res., 18: 1660-8 (2001).
120. Yamazaki, M., Neway, W. E., Ohe, T., Chen, I. W., Rowe, J. F., Hochman, J. H., Chiba, M. and Lin, J. H.: In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther., 296: 723-35 (2001).
121. Pauli Magnus, C., Murdter, T., Godel, A., Mettang, T., Eichelbaum, M., Klotz, U. and Fromm, M. F.: P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn. Schmiedebergs. Arch. Pharmacol., 363: 337-43 (2001).
122. Cui, Y., Konig, J. and Keppler, D.: Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol., 60: 934-43 (2001).
123. Doppenschmitt, S., Spahn-Langguth, H., Regardh, C. G. and Langguth, P.: Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter. J. Pharm. Res., 15: 1001-1006 (1998).
124. Wang, E. J., Casciano, C. N., Clement, R. P. and Johnson, W. W.: In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab. Dispos., 28: 316-322 (2000).
125. Eneroth, A., Astrom, E., Hoogstaate, J., Schrenk, D., Conrad, S., Kauffmann, H. M. and Gjellan, K.: Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur. J. Pharm. Sci., 12: 205-214 (2001)
126. Fernandes, P. B.: Technological advances in high-throughput screening. Curr. Opin. Chem. Biol., 2: 597-603 (1998).
127. Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O. and Serabjit-Singh, C. S.: Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther., 299: 620-628 (2001).
128. Seelig, A. and Landwojtowicz, E.: Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci., 12: 31-40 (2000).
129. Ekins, S., Waller, C. L., Swaan, P. W., Cruciani, G., Wrignton, S. A. and Wikel, J. H.: Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods, 44: 251-272 (2000).
130. Sugiyama, Y., Kato, Y. and Ito, K.: Quantitative prediction: metabolism, transport in the liver. in “Preclinical and clinical evaluation of drug-drug interactions'' Vol II in Advances in drug development. ISE Press, Inc. in press.
131. Sugiyama, D., Kusuhara, H., Shitara, Y., Abe, T., Meier, P. J., Sekine, T., Endou, H., Suzuki, H. and Sugiyama, Y.: Characterization of the efflux transport of 17b-estradiol-D-17b-glucuronide from the brain across the blood-brain barrier. J. Pharmacol. Exp. Ther., 298: 316-322 (2001).
132. Hasegawa, M., Kusuhara, H., Sugiyama, D., Ito, K., Ueda, S., Endou, H. and Sugiyama, Y.: Functional involvement of rat organic anion transporter 3 (rOAT3) in the renal uptake of organic anions. J. Pharmacol. Exp. Ther., 300: 746-53 (2002).
133. Nagata, Y., Kusuhara, H., Endou, H. and Sugiyama, Y.: Expression and functional characterization of rat organic anion transporter 3 (Slc22a8) in the choroids plexus. Mol. Pharmacol., 61: 982-988 (2002).
134. Boyd, R. A., Stern, R. H., Stewart, B. H., Wu, X., Reyner, E. L., Zegarac, E. A., Randinitis, E. J. and Whitfield, L.: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J. Clin. Pharmacol., 40: 91-98 (2000).
135. Malingre, M. M., Richel, D. J., Beijnen, J. H., Rosing, H., Koopman, F. J., Huinink, W. W. T. B., Schot, M. E. and Schellens, J. H. M.: Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol., 19: 1160-1166 (2001).
136. Meerum Terwogt, J. M., Malingre, M. M., Beijnen, J. H., Ten Bokkel Huinink, W. W., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M. and Schellens, J. H.: Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer. Res., 5: 3379-3384 (1999).
137. Siedlik, P. H., Olson, S. C., Yang, B. B. and Stern, R. H.: Erythromycin coadministration increases plasma atorvastatin concentrations. J. Clin. Pharmacol., 39: 501-4 (1999).
138. Freeman, D. J., Martell, R., Carruthers, S. G., Heinrichs, D., Keown, P. A. and Stiller, C. R.: Cyclosporin-erythromycin interaction in normal subjects. Br. J. Clin. Pharmacol., 23: 776-778 (1987).
139. Gupta, S. K., Bakran, A., Johnson, R. W. G. and Rowland, M.: Erythromycin enhances the absorption of cyclosporin. Br. J. Clin. Pharmacol., 25: 401-402 (1988).
140. Gupta, S. K., Bakran, A., Johnson, R. W. G. and Rowland, M.: Cyclosporin-erythromycin interaction in renal transplant patients. Br. J. Clin. Pharmacol., 27: 475-481 (1989).
141. Davit, B., Reynolds, K., Yuan, R., Ajayi, F., Conner, D., Fadiran, E., Gillespir, B., Sahajwalla, C., Huang, S. and Lesko, L. J.: FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling. J. Clin. Pharmacol., 39: 899-910 (1999).
142. Grub, S., Bryson, H., Goggin, T., Ludin, E. and Jorga, K.: The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur. J. Clin. Pharmacol., 57: 115-121 (2001).
143. Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., Roberts, J. P. and Hebert, M. F.: Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther., 62: 41-49 (1997).
144. Westphal, K., Weinbrenner, A., Giessmann, T., Stuhr, M., Franke, G., Zschiesche, M., Oertel, R., Terhaag, B., Kroemer, H. K. and Siegmund, W.: Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther., 68: 6-12 (2000).
145. Gramatte, T. and Oertel, R.: Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin. Pharmacol. Ther., 66: 239-245 (1999).
146. Hamman, M. A., Bruce, M. A., Haehner-Daniels, B. D. and Hall, S. D.: The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther., 69: 114-121 (2001).
147. Hebert, M. F., Fisher, R. M., Marsh, C. L., Dressler, D. and Bekersky, I.: Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J. Clin. Pharmacol., 39: 91-96 (1999).
148. Westphal, K., Weinbrenner, A., Zschiesche, M., Franke, G., Knoke, M., Oertel, R., Fritz, P., von Richter, O., Warzok, R., Hachenberg, T., Kauffman, H.M., Schrenk, D., Terhaag, B., Kroemer, H. K. and Siegmund, W.: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug-drug interaction. Clin. Pharmacol. Ther., 68: 345-355 (2000).